May 22, 2014
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the Jefferies 2014 Global Healthcare Conference on
June 4, 2014
3:30 p.m. Eastern Time
in New York.
A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at
. Replays of the presentation will be available at the same location for 30 days following the conference.
About Mirati Therapeutics
Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using a proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates, including MGCD265 and MGCD516, which are orally bioavailable, multi-targeted kinase inhibitors with distinct target profiles, and mocetinostat, an orally bioavailable, spectrum-selective histone deacetylase inhibitor. More information is available at
SOURCE Mirati Therapeutics, Inc.